domingo, 5 de julio de 2015

WHO Pharmaceuticals Newsletter No. 3, 2015




OMS, 4 de julio de 2015



Contenido



Asuntos regulatorios

Agomelatine ................................................................................... .....5


Amiodarone and hepatitis C treatments containing sofosbuvir ..................... .........5


Amphetamines and methylphenidate ............................................................7


Asunaprevir and daclatasvir hydrochloride ..................................................... 7


Azilsartan ............................................................................................7


BioCSL Fluvax® .....................................................................................8


Cefotaxime sodium ................................................................................8


Clopidogrel sulphate containing medicines .....................................................8


Codeine-containing medicines ...................................................................8


Cyclophosphamide hydrate .......................................................................9


Duloxetine hydrochloride.......................................................................... 9


Epoetin beta.................................................................................... ...10


Ferumoxytol  .................................................................................... ..10


Hydroxyzine-containing medicines ............................................................. 11


Methylphenidate ................................................................................. .11


Non-steroidal anti-inflammatory drugs and diclofenac ..................................12


Oral ibuprofen ................................................................................12


Panitumumab................................................................................. 13


Panitumumab and cetuximab .............................................................. 13


Pazopanib hydrochloride ...................................................................14


Pomalidomide ................................................................................14


Rebamipide (Ophthalmic solution) ........................................................14


Sevoflurane....................................................................................15


Sitagliptin phosphate hydrate ............................................................. 15


Triamcinolone acetonide ...................................................................15




Seguridad de medicamentos

Capecitabine and folic acid .............................................................. 17


Ceftolozane and tazobactam ............................................................. 17


Ceftriaxone and calcium containing diluents ............................................17


Clozapine with another antipsychotic drugs ............................................18


Dimethyl fumarate ......................................................................... 18


Flurbiprofen-containing topical pain medications ......................................19


Goldenseal (Hydrastis canadensis).........................................................19


Guaifenesin ..................................................................................20


Hydroxyzine .................................................................................20


Olanzapine pamoate ....................................................................... 21




Señales

Prucalopride and Suicidal ideation .......................................................22


Vemurafenib and Thrombocytopenia ....................................................27




Feature



Strengthening pharmacovigilance in countries: a brief report from two WHO events ....................................................................................... .......35





Dsiponible en http://bit.ly/1H4liQ9